AbbVie Seeks Approval for Atogepant for Acute Migraine Treatment in Japan AbbVie has applied for the approval of Atogepant, a treatment for acute migraine attacks in Japan. This submission is based on pivotal trial data.

AbbVie Seeks Approval for Atogepant for Acute Migraine Treatment in Japan #Japan #Tokyo #AbbVie #Migraine #Atogepant

ECLIPSE Trial Data Highlights Atogepant's Effectiveness Over Placebo for Migraine Treatment AbbVie presents promising ECLIPSE trial results at the European Headache Congress, showcasing Atogepant's superiority over placebo for acute migraine treatment.

ECLIPSE Trial Data Highlights Atogepant's Effectiveness Over Placebo for Migraine Treatment #USA #AbbVie #North_Chicago #Migraine #Atogepant

AbbVie's ECLIPSE Study Data Unveils Promising Migraine Treatment Options AbbVie reveals groundbreaking results from the ECLIPSE study, highlighting atogepant's significant efficacy in acute migraine treatment, aiming to enhance patient care.

AbbVie's ECLIPSE Study Data Unveils Promising Migraine Treatment Options #USA #AbbVie #North_Chicago #Eclipse #Atogepant

AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress AbbVie has shared significant findings from the ECLIPSE study at the European Headache Congress, highlighting Atogepant's effectiveness in treating migraines.

AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress #USA #North_Chicago #Atogepant #ECLIPSE_Study #AQUIPTA

AbbVie's Presentation of ECLIPSE Phase 3 Data Highlights Atogepant's Effectiveness for Migraine Relief AbbVie unveils Phase 3 ECLIPSE data at the European Headache Congress, showcasing Atogepant's superior efficacy over placebo for acute migraine treatment.

AbbVie's Presentation of ECLIPSE Phase 3 Data Highlights Atogepant's Effectiveness for Migraine Relief #USA #AbbVie #North_Chicago #Eclipse #Atogepant

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment AbbVie's Phase 3 ECLIPSE study reveals Atogepant's superiority to placebo in achieving pain freedom in acute migraine treatment, a significant advancement for patients.

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment #United_States #AbbVie #North_Chicago #Atogepant #ECLIPSE_Study

Neu: Atogepant zur Vorbeugung von Migräne - Gute Pillen - Schlechte Pillen Mit dem teuren Wirkstoff Atogepant einer Migräne vorzubeugen, bietet keine Vorteile gegenüber herkömmlichen Medikamenten.

#Atogepant zur Vorbeugung von #Migräne ist neu, aber auch besser? Leider nein, der teure Wirkstoff bietet keine Vorteile gegenüber herkömmlichen Medikamenten. (€) 😶‍🌫️😶‍🌫️
gutepillen-schlechtepillen.de/neu-atogepan...

AbbVie Unveils Promising New Data on Atogepant in Migraine Prevention Trials AbbVie announces new favorable data from a randomized trial on Atogepant, showing its superiority over Topiramate in migraine prevention.

AbbVie Unveils Promising New Data on Atogepant in Migraine Prevention Trials #United_States #AbbVie #North_Chicago #Atogepant #Topiramate

AbbVie's Atogepant Shows Superiority Over Topiramate in Migraine Prevention Trials AbbVie has announced groundbreaking results from their Phase 3 TEMPLE study, showing that Atogepant outperforms Topiramate in migraine prevention. This can revolutionize treatment options for millions.

AbbVie's Atogepant Shows Superiority Over Topiramate in Migraine Prevention Trials #USA #North_Chicago #Migraine #Atogepant #QULIPTA

▼Atogepant (AQUIPTA) zur Migräneprophylaxe Mit dem „Gepant“ ist der erste perorale Calcitonin-Gene-Related-Peptide-Rezeptorantagonist im Handel. Direktvergleiche mit anderen Migräneprophylaktika fehlen jedoch.

#Atogepant (AQUIPTA) zur #Migräneprophylaxe
Mit dem „Gepant“ ist der erste perorale Calcitonin-Gene-Related-Peptide-Rezeptorantagonist im Handel. Direktvergleiche mit anderen Migräneprophylaktika fehlen jedoch.
www.arznei-telegramm.de/html/2025_04...

arznei-telegramm 04/2025 Inhaltsverzeichnis

Die April-Ausgabe ist erschienen – Themen: Neue „Real-World“-Daten zu #NOAK versus #Phenprocoumon – #Atogepant (#AQUIPTA) zur #Migräneprophylaxe – Unzuverlässige #Glukosemessung durch #Smartwatch & Co. – u.a.
www.arznei-telegramm.de/archive/arcc...

Atogepant: Erstes Gepant zur Migräneprophylaxe verfügbar Gepante sind eine neue Wirkstoffklasse zur Behandlung von Migräne. Mit Atogepant ist der erste Vertreter zur Prophylaxe im Handel. Der orale CGRP-Reze...

Gepante sind eine neue Wirkstoffklasse zur Behandlung von #Migräne. Mit #Atogepant ist der erste Vertreter zur Prophylaxe im Handel. Der orale CGRP-Rezeptorantagonist kann bei episodischer und chronischer Migräne verordnet werden.

We spoke to Dr. Jessica Ailani about the TANDEM study, which shared data on #ubrogepant for #migraine acute treatment in patients using #atogepant for migraine prevention. Access the interview below!
Open Access manuscript: headachejournal.onlinelibrary.wiley.com/doi/10.1111/...
youtu.be/2dmEma5keYA

Howard G. Smith MD, AM on Instagram: "Migraine Medication Gives Immediate Relief Atogepant is an oral CGRP receptor antagonist, that is a calcitonin gene-related peptide receptor antagonist, that wor... 0 likes, 0 comments - drhowardsmithreports on January 9, 2025: "Migraine Medication Gives Immediate Relief Atogepant is an oral CGRP receptor antagonist, that is a calcitonin gene-related peptide rec...

Migraine Medication Gives Immediate Relief: atogepant reduced the incidence of migraine on the first day of therapy by as much as 50%. #migraine #atogepant #cgrp
www.instagram.com/drhowardsmit...

日本人片頭痛患者におけるatogepantの長期安全性を確認した新しい試験結果 アッヴィが発表したatogepantに関する第III相試験の結果、日本人片頭痛患者における長期安全性と忍容性が確認されました。

日本人片頭痛患者におけるatogepantの長期安全性を確認した新しい試験結果 #東京都 #港区 #片頭痛 #アッヴィ #atogepant

アッヴィが発表したatogepantに関する第III相試験の結果、日本人片頭痛患者における長期安全性と忍容性が確認されました。